Fusion Antibodies PLC Block admission six monthly return (4463G)
April 01 2022 - 2:01AM
UK Regulatory
TIDMFAB
RNS Number : 4463G
Fusion Antibodies PLC
01 April 2022
1 April 2022
Fusion Antibodies plc
("Fusion" or the "Company")
Block admission six monthly return
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical
antibody discovery, engineering and supply for both therapeutic
drug and diagnostic applications, announces the following
information in connection with its block admission pursuant to AIM
Rule 29 and Schedule Six of the AIM Rules for Companies.
Name of company: Fusion Antibodies plc
Name of scheme: Historic options, EMI and Unapproved
Employee Share Option Scheme,
as announced on 27 September
2021
--------------------------------------
Period of return: From 1 October 2021 to 1 April
2022
--------------------------------------
Number and class of securities 917,083 ordinary shares of 4
not issued under the scheme pence each in the Company ("Ordinary
at the beginning of the period: Shares")
--------------------------------------
Number of securities issued 120,000 Ordinary Shares
under the scheme during the
period:
--------------------------------------
Number of options under the Options over 10,000 Ordinary
scheme that have lapsed during Shares
the period:
--------------------------------------
Balance under the scheme of 787,083 Ordinary Shares
securities not yet issued at
the end of the period:
--------------------------------------
Number and class of securities 917,083 Ordinary Shares on 27
originally admitted and the September 2021
date of admission:
--------------------------------------
Contact name and telephone number: James Fair, CFO via Walbrook
PR
+44 (0)20 7933 8780
--------------------------------------
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Simon Douglas, Chairman Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited Tel: +44 (0)20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate
Finance)
Tony Quirke (Sales and Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741
001
Paul McManus Mob: +44 (0)7980 541
893
About Fusion Antibodies plc
Fusion is a Belfast-based Collaborative Research Organisation
("CRO") company, listed on AIM, providing a range of antibody
engineering services for the development of antibodies for both
therapeutic drug and diagnostic applications.
Fusion provides a broad range of services in antibody
generation, development, characterisation, optimisation, and
small-scale production. These services include antigen expression,
purification and sequencing, antibody humanisation using Fusion's
proprietary CDRx(TM) platform and cell line development, producing
antibody generating stable cell lines optimised for use downstream
by the customer to produce material for clinical trials. Since
2012, the Company has successfully sequenced and expressed over 250
antibodies and successfully completed over 200 humanisation
projects for its international customer base, which has included
eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in
combining the latest technological advances with cutting edge
science. In this work our world-class humanization and antibody
optimization platforms harness the power of natural somatic
hypermutation (SHM) to ensure the best molecule goes to the clinic.
Fusion Antibodies' growth strategy is based on enabling Pharma and
Biotech companies get to the clinic more effectively, using
molecules with optimized therapeutic profile and enhanced potential
for successful development and approval and, ultimately, on
speeding up the drug discovery and development process. Fusion's
use of SHM to create a fully human antibody library to capture the
human antibody repertoire will address a continuing market need in
antibody discovery,
Fusion Antibodies' emphasis on antibody therapeutics is based on
the size and growth rate in the sector, with the market valued at
$135.4 billion in 2018 and forecast to surpass $300 billion by
2025, a CAGR of 14.26%. As of May 2021, there were 100 approved
antibody therapies on the market and more than 570 antibody
therapies in clinical development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLRBKCBPQBKDDNB
(END) Dow Jones Newswires
April 01, 2022 02:01 ET (06:01 GMT)
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Sep 2023 to Sep 2024